Details of the Drug Combination

General Information of Drug Combination (ID: DC2T79V)

Drug Combination Name
Silver sulfadiazine Trioxsalen
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Silver sulfadiazine   DMVTHWQ Trioxsalen   DM53BDW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 15.19
Bliss Independence Score: 15.19
Loewe Additivity Score: 29.08
LHighest Single Agent (HSA) Score: 29.08

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Silver sulfadiazine
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [2]
Skin ulcer ME60.Z Approved [3]
Silver sulfadiazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Dihydropteroate synthetase (Bact folP) TT4ILYC DHPS_ECOLI Binder [6]
------------------------------------------------------------------------------------
Indication(s) of Trioxsalen
Disease Entry ICD 11 Status REF
Skin sensitivity to sun N.A. Approved [4]
Vitiligo ED63.0 Approved [5]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4126).
3 Silver sulfadiazine FDA Label
4 Trioxsalen FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4.